News
ARWR
67.98
-4.19%
-2.97
Weekly Report: what happened at ARWR last week (0406-0410)?
Weekly Report · 3d ago
H.C. Wainwright Reaffirms Their Buy Rating on Arrowhead Pharmaceuticals (ARWR)
TipRanks · 04/07 14:25
Weekly Report: what happened at ARWR last week (0330-0403)?
Weekly Report · 04/06 10:21
Arrowhead Pharmaceuticals (ARWR) Is Up 5.9% After Durable Two-Year Plozasiran Data in Severe Hypertriglyceridemia
Simply Wall St · 04/06 07:15
A Look At Arrowhead Pharmaceuticals (ARWR) Valuation After New Plozasiran Phase 2 Extension Data
Simply Wall St · 04/04 12:24
Weekly Report: what happened at ARWR last week (0323-0327)?
Weekly Report · 03/30 10:21
Reported Saturday, Arrowhead's Plozasiran Delivers 83% Median Triglyceride Reduction In Severe hypertriglyceridemia Patients With Zero Acute Pancreatitis Events Over Two-Year Open-Label Extension Study
Benzinga · 03/30 07:28
Arrowhead presents long-term efficacy, safety data for plozasiran
TipRanks · 03/29 16:00
How Investors May Respond To Arrowhead Pharmaceuticals (ARWR) Plozasiran’s Two-Year Triglyceride and Safety Data
Simply Wall St · 03/28 19:10
Arrowhead says plozasiran cuts triglycerides up to 83% in two-year extension study
Reuters · 03/28 14:30
Arrowhead Pharmaceuticals Presents New Long-Term Efficacy and Safety Data for Plozasiran Across a Spectrum of Hypertriglyceridemia at the American College of Cardiology’s 75th Annual Scientific Session and Expo
Barchart · 03/28 09:30
Maintaining Buy on Arrowhead: APOC3-Driven Value Unlocked by Shasta-3/4 Amid Obesity Program Uncertainty
TipRanks · 03/27 09:45
Ionis Pharmaceuticals Repriced Drug Ahead Of Key FDA Decision Signals Push Into Larger Market
Benzinga · 03/26 17:47
Analysts Conflicted on These Healthcare Names: Maze Therapeutics, Inc. (MAZE), Azitra Inc (AZTR) and Arrowhead Pharmaceuticals (ARWR)
TipRanks · 03/26 15:40
Wave data brings questions about Arrowhead ‘back to center stage,’ says Leerink
TipRanks · 03/26 15:30
Arrowhead price target lowered to $81 from $84 at BofA
TipRanks · 03/26 15:20
Arrowhead Pharmaceuticals: Transition Phase With Moderate Upside Ahead
Seeking Alpha · 03/26 11:13
Assessing Arrowhead Pharmaceuticals (ARWR) Valuation After A Strong One Year Shareholder Return
Simply Wall St · 03/26 08:10
AAR Foods Posts Upbeat Q3 Earnings, Joins Braze, Arm Holdings And Other Big Stocks Moving Higher On Wednesday
Benzinga · 03/25 18:32
Analysts Conflicted on These Healthcare Names: Cibus (CBUS), Arrowhead Pharmaceuticals (ARWR) and Tarsus Pharmaceuticals (TARS)
TipRanks · 03/25 17:50
More
Webull provides a variety of real-time ARWR stock news. You can receive the latest news about Arrowhead Pharma through multiple platforms. This information may help you make smarter investment decisions.
About ARWR
Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. The Company's therapies, using a broad portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, trigger the RNA interference (RNAi) mechanism to induce rapid, deep and durable knockdown of target genes. The Company's Targeted RNAi Molecule (TRiMTM) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. It is focused on various therapeutic areas, such as cardiometabolic, pulmonary, liver, muscle and central nervous system. It has around 16 clinical-stage investigational medicines (wholly owned and partnered), which range in development stage from Phase I to Phase III. The Company's pipeline products include Plozasiran, Zodasiran, Olpasiran, ARO-RAGE, ARO-MMP7, GSK-4532990, Fazirsiran, GSK5637608, ARO-CFB, ARO-INHBE, ARO-C3, ARO-PNPLA3, ARO-DUX4, ARO-DM1 and ARO-ATXN2.